

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:902194 CAPLUS Full-text

DN 141:395590

TI Preparation of benzoxazepine compounds as RFRP receptor antagonists

IN Itoh, Fumio; Hinuma, Shuji; Kanzaki, Naoyuki; Mabuchi, Hiroshi; Yoshida, Hiromi; Matsumoto, Hirokazu; Wakabayashi, Takeshi

PA Takeda Chemical Industries Ltd., Japan

SO PCT Int. Appl., 226 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004091628	A1	20041028	WO 2004-JP5406	20040415
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004331659	A	20041125	JP 2004-120246	20040415
	EP 1623710	A1	20060208	EP 2004-727766	20040415
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 2007129348	A1	20070607	US 2005-553273	20051012
PRAI	JP 2003-114313	A	20030418		
	WO 2004-JP5406	W	20040415		
OS	MARPAT 141:395590				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (un)substituted aromatic ring; B = (un)substituted benzene ring; X = O, S(0)n, NR3; n = 0-2; R3 = H, (un)substituted hydrocarbon group, etc.; R1, R2 = H, (un)substituted hydrocarbon group, etc.] were prepared. For example, reductive amination of compound trans-II·HCl [Q = H] with 3-phenylpropanaldehyde afforded compound trans-II·HCl [Q = 3-phenylpropyl]. In human RFRP-3 (RFamide-related peptide-3) binding inhibition assays, the IC50 value was <1 μM. Compds. I are claimed useful as analgesics, prolactin secretion regulators, etc. Formulations are given.


IT 762468-62-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 762468-62-6 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 782467-01-0P 782467-03-2P 782467-53-2P

782467-63-4P 782467-69-0P 782467-75-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782467-01-0 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-03-2 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-methyl-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-53-2 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-63-4 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-69-0 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]methylamino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-75-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

IT 782468-58-0P 782468-60-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782468-58-0 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-[3-[3-[(1,1-dimethylethoxy)carbonyl](3-phenylpropyl)amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-60-4 CAPLUS

CN 1,2-Piperazinedicarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-[3-[3-[(1,1-dimethylethoxy)carbonyl](3-phenylpropyl)amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1-(1,1-dimethylethyl) 2-ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1050851 CAPLUS [Full-text](#)

DN 143:347212

TI Preparation of aryl dihydrobenzoxazepinone derivatives as progesterone receptor modulators

IN Zhang, Puwen; Wrobel, Jay Edward; Terefenko, Eugene Anthony; Kern, Jeffrey Curtis

PA Wyeth, John, and Brother Ltd., USA

SO U.S. Pat. Appl. Publ., 61 pp.



CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005215539	A1	20050929	US 2005-87051	20050322
	WO 2005095366	A1	20051013	WO 2005-US9756	20050323
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2004-555945P	P	20040324		
	US 2005-87051	A	20050322		
OS	MARPAT 143:347212				
GI					



AB Title compds. I [R1 = H, alkyl or CORA; RA = H, alkyl, alkoxy, etc.; R2 and R3 independently = H, CF3 or alkyl; R4 and R5 independently = H, alkenyl, alkynyl, etc. or together they may form a alkylspirocyclic ring or heterospirocyclic ring; R6 = benzofused heterocyclic ring, substituted Ph or heterocycle; R7 = CN, halo, NO2, etc.; Q = O, S, NR8, etc.; R8 = CN, (un)substituted alkyl, aryl, etc.; X = O, S, NR9, etc.; R9 = H or alkyl with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as progesterone receptor modulators. Thus, e.g., II was prepared by cyclization of N-[4-bromo-2-(1-hydroxy-1-thien-2-ylethyl)phenyl]-2-chloroacetamide using sodium hydride followed by palladium catalyzed coupling with 2-borono-1H-pyrrole-1-carboxylic acid 1-tert-Bu ester and cyanation using

chlorosulfonyl isocyanate. The activity of I was evaluated in vitro using T47D cell proliferation assay and it was revealed that selected compds. of the invention possessed IC50 values in the range of 14.9 up to 120.5 nM. I as progesterone receptor modulators should prove useful in the treatment of carcinomas such as but not limited to breast, colon and prostate. Pharmaceutical compns. comprising I are disclosed.

IT 865669-00-7P 865670-00-4P 865670-06-0P
865670-54-3P 865670-59-3P 865670-61-7P
865670-62-8P 865671-67-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of aryl dihydrobenzoxazepinone derivs. as progesterone

receptor

modulators)


RN 865669-00-7 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-cyano-5-(1,2,3,5-tetrahydro-5-methyl-2-oxo-5-phenyl-4,1-benzoxazepin-7-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 865670-00-4 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[5,5-bis(3-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-7-yl]-5-cyano-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 865670-06-0 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[5,5-bis(4-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-7-yl]-5-cyano-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 865670-54-8 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-cyano-5-[1,2,3,5-tetrahydro-2-oxo-5,5-diphenyl-4,1-benzoxazepin-7-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 865670-59-3 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-cyano-5-[1,2,3,5-tetrahydro-5,5-bis(4-methoxyphenyl)-2-oxo-4,1-benzoxazepin-7-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 865670-61-7 CAPLUS

CN 1H-Pyrrole-2-carbonitrile, 5-[1,2,3,5-tetrahydro-5,5-bis(4-methoxyphenyl)-1-methyl-2-oxo-4,1-benzoxazepin-7-yl]- (CA INDEX NAME)





RN 865670-62-8 CAPLUS

CN 1H-Pyrrole-2-carbonitrile, 1-methyl-5-[1,2,3,5-tetrahydro-5,5-bis(4-methoxyphenyl)-1-methyl-2-oxo-4,1-benzoxazepin-7-yl]- (CA INDEX NAME)




RN 865671-67-6 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-cyano-5-[1,2,3,5-tetrahydro-5,5-bis(4-methoxyphenyl)-2-oxo-4,1-benzoxazepin-7-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012272	A1	20050210	WO 2004-JP11293	20040730
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004260757	A1	20050210	AU 2004-260757	20040730
	CA 2534464	A1	20050210	CA 2004-2534464	20040730
	JP 2005068138	A	20050317	JP 2004-222658	20040730
	EP 1650201	A1	20060426	EP 2004-748264	20040730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1832934	A	20060913	CN 2004-80022202	20040730
	BR 2004013009	A	20061003	BR 2004-13009	20040730
	MX 2006PA01007	A	20060427	MX 2006-PA1007	20060125
	IN 2006KN00235	A	20070803	IN 2006-KN235	20060131
	NO 2006001009	A	20060502	NO 2006-1009	20060301
FRAI	JP 2003-285341	A	20030801		
	WO 2004-JP11293	W	20040730		
OS	MARPAT 142:219318				
GI					



I

AB The title compds. I (ring A and ring B each represents an optionally substituted benzene ring; ring C represents an optionally further substituted aromatic ring; R1 represents a lower alkyl optionally substituted by

optionally substituted hydroxy; X1a represents a bond or optionally substituted lower alkylene; X1b represents a bond or optionally substituted lower alkylene; X2 represents a bond, O, or S; X3 represents a bond or an optionally substituted divalent hydrocarbon group; and Y represents optionally esterified or amidated carboxy) are prepared. A process for preparing I is disclosed. Thus, (2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]methyl]-1,3-thiazol-5-yl]acetic acid was prepared in a multistep process from 2-(tert-butoxycarbonylamino)acetic acid and potassium monoethyl malonate. Comps. of this invention are said to show IC50 values of $\leq 1 \mu\text{M}$ against squalene synthase. Formulations are given.

IT 839724-80-0P 839724-83-3P 839725-04-1P
839725-12-1P 839725-13-2P 839725-46-1P
941236-35-9P 841236-36-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxazepine derivs. as squalene synthase inhibitors)

RN 839724-80-0 CAPLUS

CN Propanedioic acid, monoethyl ester, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]hydrazide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-83-3 CAPLUS


CN Butanedioic acid, monoethyl ester, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-04-1 CAPLUS
 CN 4-Thiazolepropanenitrile, 2-[[{(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- α -[[{(1,1-dimethylethyl)dimethylsilyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-12-1 CAPLUS
 CN 1,2,4-Oxadiazole-5-acetonitrile, 3-[[{(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 839725-13-2 CAPLUS
 CN 4,1-Benzoxazepine-3-ethanimidamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-hydroxy-2-oxo-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-46-1 CAPLUS

CN 4,1-Benzoxazepine-3-butanimidamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-hydroxy-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 841236-35-9 CAPLUS

CN 4,1-Benzoxazepine-3-ethanimidamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-hydroxy-2-oxo-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 841236-36-0 CAPLUS

CN 4,1-Benzoxazepine-3-propanimidamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-
7-chloro-5-(2,3-dimethoxyphenyl)- α -[[(1,1-
dimethylethyl)dimethylsilyl]oxy]-1,2,3,5-tetrahydro-N-hydroxy-2-oxo-,
(3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:902194 CAPLUS Full-text
 DN 141:395590
 TI Preparation of benzoxazepine compounds as RFRP receptor antagonists
 IN Itoh, Fumio; Hinuma, Shuji; Kanzaki, Naoyuki; Mabuchi, Hiroshi; Yoshida, Hiromi; Matsumoto, Hirokazu; Wakabayashi, Takeshi
 PA Takeda Chemical Industries Ltd., Japan
 SO PCT Int. Appl., 226 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004091628	A1	20041028	WO 2004-JP5406	20040415
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004331659	A	20041125	JP 2004-120246	20040415
	EP 1623710	A1	20060208	EP 2004-727766	20040415
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 2007129348	A1	20070607	US 2005-553273	20051012
PRAI	JP 2003-114313	A	20030418		
	WO 2004-JP5406	W	20040415		
OS	MARPAT 141:395590				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [A = (un)substituted aromatic ring; B = (un)substituted benzene ring; X = O, S(:O)n, NR3; n = 0-2; R3 = H, (un)substituted hydrocarbon group, etc.; R1, R2 = H, (un)substituted hydrocarbon group, etc.] were prepared For example, reductive amination of compound trans-II-HCl [Q = H] with 3-phenylpropanaldehyde afforded compound trans-II-HCl [Q = 3-phenylpropyl]. In human RFRP-3 (RFamide-related peptide-3) binding inhibition assays, the IC50 value was <1 µM. Compds. I are claimed useful as analgesics, prolactin secretion regulators, etc. Formulations are given.

IT 782466-03-3P 782466-05-1P 782466-07-3P
 782466-49-3P 782466-51-7P 782466-55-1P
 782466-61-9P 782467-32-7P 782467-34-9P
 782467-38-3P 782467-40-7P 782467-71-4P
 782467-77-0P 782467-85-0P 782468-11-5P
 782468-62-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782466-03-9 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-05-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782466-07-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-49-3 CAPLUS

CN Carbamic acid, [2-[3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]ethyl]-, 1,1-dimethylethyl ester, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-51-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(2-aminoethoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-55-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[(3-phenylpropyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-61-9 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl] (3-phenylpropyl)-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-32-7 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-34-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-38-3 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-40-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-methyl-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-71-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, 4-piperidiny] ester, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-77-0 CAPLUS

CN Carbamic acid, [3-[[[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl](trifluoroacetyl)amino]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-85-0 CAPLUS

CN Carbamic acid, [2-[[[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]amino]ethyl] (3-phenylpropyl)-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-11-5 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 782468-62-6 CAPLUS
 CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 782466-09-5P 782466-11-9P 782466-13-1P
 782466-15-3P 782466-17-5P 782466-19-7P
 782466-21-1P 782466-23-3P 782466-25-5P
 782466-27-7P 782466-29-9P 782466-31-3P
 782466-33-5P 782466-35-7P 782466-37-9P
 782466-39-1P 782466-41-5P 782466-43-7P
 782466-45-9P 782466-47-1P 782466-53-9P
 782466-57-3P 782466-59-5P 782466-63-1P
 782466-65-3P 782466-61-3P 782466-63-5P
 782466-65-7P 782466-67-9P 782466-69-1P
 782466-91-5P 782466-93-7P 782466-95-9P
 782466-97-1P 782466-99-3P 782467-01-0P
 782467-03-2P 782467-05-4P 782467-07-6P
 782467-09-8P 782467-11-2P 782467-13-4P
 782467-15-6P 782467-17-8P 782467-19-0P
 782467-21-4P 782467-23-6P 782467-25-8P
 782467-28-1P 782467-30-5P 782467-36-1P
 782467-42-9P 782467-53-2P 782467-63-4P
 782467-69-0P 782467-73-6P 782467-75-8P
 782467-79-2P 782467-81-6P 782467-93-8P
 782467-87-2P 782467-89-4P 782467-91-8P
 782467-97-4P 782467-99-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782466-09-5 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-(pentylamino)propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-11-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(phenylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-13-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-5-[3-[3-[(2-furanylmethyl)amino]propoxy]-2-methoxyphenyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-15-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-thienylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-17-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-pyridinylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-19-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-naphthalenylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-21-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(1-naphthalenylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-23-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(4-phenylbutyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-25-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[(3-(4-chlorophenyl)propyl)amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-27-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (1R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-29-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (1R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-31-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-33-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-phenoxyethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-35-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-phenylethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-37-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2E)-3-phenyl-2-propenyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




● HCl

RN 782466-39-1 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(4-methoxyphenyl)propyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B


— OMe

RN 782466-41-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-methoxyphenyl)propyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 1-B

—OMe

RN 782466-43-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-methoxyphenyl)propyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-45-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-{3-[[3-(3,4-dimethoxyphenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



● HCl


—OMe

RN 782466-47-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[3-[(2-(1H-indol-3-yl)ethyl)amino]propoxy]-2-methoxyphenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

PAGE 1-A



PAGE 1-B


● HCl



RN 782466-53-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[(2-phenylethyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-57-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[(4-phenylbutyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-59-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[methyl(3-phenylpropyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-63-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-65-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-7-phenyl-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-81-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-83-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(phenylmethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-85-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(2-phenylethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-87-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-N-methyl-2-oxo-N-(phenylmethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-89-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-phenyl-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-91-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(2-pyridinylmethyl)-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782466-93-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-propyl-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-95-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N,N-diethyl-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-97-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(2-methoxyphenyl)methyl]-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-99-3 CAPLUS

CN Piperidine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-01-0 CAPLUS

CN Piperazine, 1-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-03-2 CAPLUS

CN Piperazine, 1-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-methyl-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-05-4 CAPLUS

CN Morpholine, 4-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-07-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(4-piperidinylmethyl)-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-09-8 CAPLUS

CN 1,4'-Bipiperidine, 1'-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-11-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(2-aminoethyl)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-13-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(3-aminopropyl)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, dihydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-15-6 CAPLUS

CN 4-Piperidinamine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-17-8 CAPLUS

CN 1H-1,4-Diazepine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]hexahydro-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-19-0 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-1-(2,2-dimethylpropyl)-1,5-dihydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-3-[2-oxo-2-(4-piperidinyl)ethyl]-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-21-4 CAPLUS

CN Glycine, N-[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-23-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-(dimethylamino)propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-25-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-28-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]-2-oxo-, dihydrochloride, (3R,5S)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-30-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[2-(dimethylamino)ethoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-36-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-42-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-1-methyl-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-53-2 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-63-4 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-5-[3-[3-[(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-69-0 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-5-[3-[3-[(2-chlorophenyl)propyl]methylamino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-73-6 CAPLUS

CN 4-Piperidinol, 1-[[{(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-75-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[{(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-79-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[3-[(phenylmethyl)amino]propyl]amino]methyl]phenyl]-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-81-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[3-[(2-phenylethyl)amino]propyl]amino]methyl]phenyl]-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-83-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[[3-(3-phenylpropyl)amino]propyl]amino]methyl]phenyl]-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-87-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[[2-(3-phenylpropyl)amino]ethyl]amino]methyl]phenyl]-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-89-4 CAPLUS

CN Carbamic acid, [2-[[[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]amino]ethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-91-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[2-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-97-4 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-5-[2-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-99-6 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 782468-96-6 782469-00-5 782469-02-7
 782469-04-3 782469-06-1 782469-52-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (preparation of benzoxazepine compds. as agents for controlling function of
 RFRP receptor)
 RN 782468-96-6 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-
 fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-
 phenylpentyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 782469-00-5 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-
 fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2E)-3-phenyl-
 2-propenyl]amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX
 NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 782469-02-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-phenylpentyl)amino]propoxy]phenyl]-2-oxo-N-propyl-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782469-04-9 CAPLUS

CN Piperidine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-phenylpentyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782469-06-1 CAPLUS

CN 4-Piperidinol, 1-[[(3R, 5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-phenylpentyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782469-52-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R, 5S)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 782468-13-7P 782468-15-9P 782468-17-1P
782468-19-3P 782468-21-7P 782468-23-9P
782468-27-3P 782468-29-5P 782468-31-9P
782468-50-2P 782468-56-8P 782468-58-0P
782468-60-4P 782468-68-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782468-13-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R, 5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-15-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-nitrophenyl)sulfonyl](2-phenoxyethyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-17-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-phenoxyethyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-19-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-21-7 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-phenyl-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl] (3-phenylpropyl)-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-23-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-7-phenyl-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-27-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-29-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(phenylmethyl)-, (3R,5S)-rel- (CA INDEX NAME)

Relative stereochemistry.




CN Glycine, N-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)

CN 4,1-Benzoxazepine-1,3(5H)-diacetic acid, 7-chloro-2,3-dihydro-5-[2-methoxy-3-[3-[[[(2-nitrophenyl)sulfonyl](3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, α 1-(1,1-dimethylethyl) α 3-methyl ester, (3R,5S)-rel- (9CI)
(CA INDEX NAME)

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, 4-piperidinyl ester, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 782468-58-0 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-[3-[3-[(1,1-dimethylethoxy)carbonyl](3-phenylpropyl)amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-60-4 CAPLUS

CN 1,2-Piperazinedicarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-[3-[3-[(1,1-dimethylethoxy)carbonyl](3-phenylpropyl)amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1-(1,1-dimethylethyl) 2-ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:648392 CAPLUS [Full-text](#)

DN 141:190808

TI Preparation of aromatic ring-fused cyclic compounds as TGR5 receptor agonists

IN Itoh, Fumio; Hinuma, Shuji; Kanzaki, Naoyuki; Miki, Takashi; Kawamata, Yuji; Oi, Satoru; Tawaraishi, Taisuke; Ishichi, Yuji; Hirohashi, Mariko

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 337 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004067008	A1	20040812	WO 2004-JP706	20040127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	CA 2514547	A1	20040812	CA 2004-2514547	20040127
	JP 2004346059	A	20041209	JP 2004-18643	20040127
	EP 1591120	A1	20051102	EP 2004-705536	20040127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006199795	A1	20060907	US 2005-543997	20051031
PRAI	JP 2003-19272	A	20030128		
	JP 2003-124311	A	20030428		
	WO 2004-JP706	W	20040127		
OS	MARPAT 141:190808				
GI					



AB It is intended to provide G protein-coupled receptor (TGR5) agonists containing fused ring compds. represented by the following general formula (I), salts or prodrugs thereof (wherein the ring A represents an optionally substituted aromatic ring; and the ring B represents a 5- to 8-membered ring having one or more substituents). Also disclosed are regulators for physiological functions involving TGR5, preventives and/or remedies for various diseases involving TGR5, cytokine production inhibitors, GLP-1 secretion promoters, insulin secretion promoters, appetite depressants, pancreas regenerants, promoters for pancreas β -cell differentiation or proliferation, insulin resistance improvers, or immunosuppressants. containing the compds. I. In particular disclosed are preventives and/or remedies containing the compds. I for heart failure, myocardial infarction, acute kidney failure, angina pectoris, arrhythmia, bronchial asthma, chronic obstructive pulmonary disease, arteriosclerosis, chronic articular rheumatism, diabetes, obesity, insulin secretion failure, pancreas fatigue, gastric ulcer, ulcerative colitis, allergy, osteoarthritis, erythematodes, or excessive immune reaction after transplant surgery. The compds. I are also useful for screening ligands, agonists, or antagonists of TGR5. Thus, 0.1 g 2-[trans-7-chloro-5-(3-formylphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-N-(2-fluorobenzyl)acetamide was reduced by NaBH₄ in MeOH at room temperature for 30 min to give 76 mg 2-[trans-7-chloro-5-(3-hydroxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-N-(2-fluorobenzyl)acetamide (II). II at 1 μ M increased the production of cAMP in CHO cells expressing human TGR5

by 128%. Pharmaceutical formulations containing specific compound I were also prepared

IT 737785-10-3P 737785-11-4P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists,

cytokine production inhibitors and appetite depressants)

RN 737785-10-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 737785-11-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 737785-21-6P 737785-22-7P 737785-27-2P

737785-29-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists,


cytokine production inhibitors and appetite depressants)

RN 737785-21-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-1-[3-

(acetyloxy)-2,2-dimethylpropyl]-7-chloro-N-[(2-fluorophenyl)methyl]-
1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-22-7 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-27-2 CAPLUS


CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-3-[2-oxo-2-[[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 737785-29-4 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



IT	215186-85-9P	215186-86-0P	215186-87-1P
	215186-98-2P	215186-89-3P	737783-99-2P
	737784-24-6P	737784-27-9P	737784-29-1P
	737784-36-0P	737784-37-1P	737784-38-2P
	737784-39-3P	737784-40-6P	737784-41-7P
	737784-42-8P	737784-43-9P	737784-44-0P
	737784-80-4P	737784-81-5P	737784-82-6P
	737784-83-7P	737784-85-9P	737784-86-0P
	737784-87-1P	737784-88-2P	737784-89-3P
	737784-90-6P	737784-91-7P	737784-92-8P
	737784-93-9P	737784-94-0P	737784-95-1P
	737784-97-3P	737784-98-4P	737784-99-5P
	737785-00-1P	737785-02-3P	737785-03-4P
	737785-06-7P	737785-08-9P	737785-09-0P
	737785-12-5P	737785-13-6P	737785-16-9P
	737785-17-0P	737785-18-1P	737785-19-2P
	737785-20-5P	737785-23-8P	737785-24-9P
	737785-26-1P	737785-28-3P	737785-30-7P
	737785-31-8P	737785-32-9P	737785-23-0P
	737785-34-1P	737785-35-2P	737785-37-4P
	737785-38-5P	737785-39-6P	737785-40-9P
	737785-41-0P	737785-42-1P	737785-43-5P
	737788-77-1P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists, cytokine production inhibitors and appetite depressants)

RN 215186-85-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215186-86-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[(methylsulfonyl)amino]methyl]phenyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215186-87-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[trifluoroacetyl]amino]methyl]phenyl]-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-88-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-89-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[[[(methylamino)carbonyl]amino]methyl]phenyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737783-99-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-(3-aminophenyl)-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-24-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[(1-oxopropyl)amino]methyl]phenyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-27-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[(1-oxobutyl)amino]methyl]phenyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-29-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-36-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-37-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(phenylmethyl)-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-38-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-propyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-39-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-methyl-2-oxo-N-(phenylmethyl)-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-40-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-pyridinylmethyl)-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-41-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-(cyclohexylmethyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-42-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-phenylethyl)-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-43-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-(1-methyl-1-phenylethyl)-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-44-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[[4-(methylsulfonyl)phenyl]methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 737784-80-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[(tetrahydro-2-

furanyl)methyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-81-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[[2-(trifluoromethyl)phenyl]methyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-82-6 CAPLUS

CN Glycine, N-[[[(3R,5R)-5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-83-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-85-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-(cyclopentylmethyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-86-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-(cyclopropylmethyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-87-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[[2-(methylthio)phenyl]methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-88-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[[2-(methylsulfonyl)phenyl]methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-89-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[[3-(trifluoromethyl)phenyl]methyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-90-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-N-[(2-bromophenyl)methyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-91-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-chlorophenyl)methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-92-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(2-methoxyphenyl)methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-93-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-
N-[(2,6-difluorophenyl)methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-
oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-94-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-
1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2,2,2-trifluoroethyl)-,
(3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 737784-95-1 CAPLUS

CN Glycine, N-[[(3R,5R)-5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-

dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-,
rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-97-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-3-[2-oxo-2-[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-98-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(cyclohexylmethyl)amino]-2-oxoethyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-99-5 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-(3,4-dihydro-2(1H)-isoquinolinyl)-2-oxoethyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-00-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-(2-fluorophenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-02-3 CAPLUS

CN Acetamide, N-[[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[[[(2-fluorophenyl)methyl]amino]carbonyl]amino]methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-03-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(2-amino-2-oxoethoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-06-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[2-(dimethylamino)-2-oxoethoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-08-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-oxo-2-[(2-phenylethyl)amino]ethoxy]phenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-09-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-2-oxoethoxy]-2-methoxyphenyl]-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-12-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-
N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 737785-13-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[4-[(acetylamino)methyl]phenyl]-7-chloro-
N-[(2,2-dimethylpropyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-
, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-16-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-
N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-,
(3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-17-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-propyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-18-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(2-thienylmethyl)-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 737785-19-2 CAPLUS

CN Carbamic acid, [(3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-

2-oxoethyl]-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-20-5 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-propyl-4,1-benzoxazepin-5-yl]phenyl)methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-23-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(3-hydroxy-2-dimethylpropyl)-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-24-9 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-26-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-3-[2-oxo-2-[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-28-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-[2,2-dimethyl-3-[(methylsulfonyl)oxy]propyl]-1,2,3,5-tetrahydro-2-oxo-3-[2-oxo-2-[[[(2-(trifluoromethyl)phenyl)methyl]amino]ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-30-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-cyclohexyl-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-31-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-thienylmethyl)-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-32-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(3-thienylmethyl)-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-33-0 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-(2-furanylmethyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 737785-34-1 CAPLUS


CN Cyclohexanecarboxylic acid, 4-[[[5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 737785-35-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-37-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-(4H-1,2,4-triazol-4-ylmethyl)phenyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-38-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-(1H-imidazol-1-ylmethyl)phenyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-39-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(6-methoxy-2-naphthalenyl)methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-40-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(2-quinolinylmethyl)-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 737785-41-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-

1-(9H-fluoren-9-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-42-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[[5-(2-methoxyphenyl)-2-furanyl]methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737785-43-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-1-([2,3'-bithiophen]-5-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737788-77-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[[4-(trifluoromethyl)phenyl]methyl]-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 215185-18-5 737788-15-8


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists, cytokine production inhibitors and appetite depressants)

RN 215185-18-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[[4-(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-15-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 737784-48-4P 737784-51-9P 737784-52-0P

737784-54-2P 737784-56-4P 737784-60-0P

737784-61-1P 737784-62-2P 737784-75-7P

737784-76-8P 737784-77-9P 737784-78-0P

737784-79-1P 737785-01-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists, cytokine production inhibitors and appetite depressants)

RN 737784-48-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 737784-51-9 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-52-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(1-methylethyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 737784-54-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(2-thienylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 737784-56-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-60-0 CAPLUS

CN 4,1-Benzoxazepine-1(5H)-acetic acid, 5-[3-(aminomethyl)phenyl]-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-, 2,2-dimethylpropyl ester, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 737784-61-1 CAPLUS

CN 4,1-Benzoxazepine-1(5H)-acetic acid, 7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-, 2,2-dimethylpropyl ester, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-62-2 CAPLUS

CN 4,1-Benzoxazepine-1(5H)-acetic acid, 7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-2,3-dihydro-2-oxo-3-[2-oxo-2-[[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]-, 2,2-dimethylpropyl ester, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 737784-75-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(6-methoxy-2-naphthalenyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 737784-76-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(2-quinolinylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-77-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(9H-fluoren-9-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-78-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[[3-(2-methoxyphenyl)-2-furanyl]methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-79-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-[(2,3'-bithiophen)-5-ylmethyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-01-2 CAPLUS

CN Carbamic acid, [[(3R,5R)-5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, 9H-fluoren-9-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L13 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:22711 CAPLUS Full-text

DN 138:83384

TI Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase

IN Sugiyama, Yasuo; Nishimoto, Tomoyuki; Kiyota, Yoshihiro

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 121 pp.

CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003002147	A1	20030109	WO 2002-JP6495	20020627
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2451163	A1	20030109	CA 2002-2451163	20020627
	AU 2002313277	A1	20030303	AU 2002-313277	20020627
	JP 2003081873	A	20030319	JP 2002-188133	20020627
	EP 1407782	A1	20040414	EP 2002-738822	20020627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004204500	A1	20041014	US 2003-480707	20031211
	US 2006241096	A1	20061026	US 2006-473560	20060623
PRAI	JP 2001-197419	A	20010628		
	WO 2002-JP6495	W	20020627		
	US 2003-480707	A3	20031211		
OS	MARPAT 138:83384				
AB	Preventives/remedies for organ functional disorders, preventives/remedies for organ dysfunction and preventives/remedies for obesity and sequels thereof which contain a compound having an effect of increasing ubiquinone, its salt or prodrugs of the same; and ubiquinone increasing agents containing a compound having a squalene synthase inhibitory effect, its salt or prodrugs of the same.				
IT	189059-19-6 189060-37-5 189060-41-1 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase)				
RN	189059-19-6 CAPLUS				
CN	4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (CA INDEX NAME)				


Absolute stereochemistry.



RN 189060-37-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-41-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:368342 CAPLUS Full-text

DN 136:359669

TI High-density lipoprotein-cholesterol level elevating agent

IN Nishimoto, Tomoyuki; Tozawa, Ryuichi; Kori, Masakuni; Amano, Yuichiro

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002038180	A1	20020516	WO 2001-JP9802	20011109
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RM:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2428669	A1	20020516	CA 2001-2428669	20011109
	AU 2002012741	A5	20020521	AU 2002-12741	20011109
	JP 2002205956	A	20020723	JP 2001-344074	20011109
	EP 1332763	A1	20030806	EP 2001-981043	20011109
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2004063750	A1	20040401	US 2003-416239	20030506
PRAI	JP 2000-342607	A	20001109		
	WO 2001-JP9802	W	20011109		

OS MARPAT 136:359669

AB Disclosed is a novel high-d. lipoprotein (HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory effect. The HDL-cholesterol-elevating effect of N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl]acetyl]piperidine-4-acetic acid (I) in common marmoset was examined. Also, a tablet containing I 50, D-mannitol 50, corn starch 33.9, croscarmellose sodium 40, hydroxypropyl cellulose 5.5, and magnesium stearate 0.6 mg was prepared.


IT 189059-19-6 189059-70-9 189060-37-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(high-d. lipoprotein-cholesterol level elevating agents containing squalene synthase inhibitors)

RN 189059-19-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-70-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-37-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2001:935587 CAPLUS [Full-text](#)
 DN 136:69829

TI Preparation of dialkoxyphenyloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents

IN Kori, Masakuni; Miki, Takashi; Nishimoto, Tomoyuki; Tozawa, Ryuichi

PA Takeda Chemical Industries, Ltd, Japan

SO PCT Int. Appl., 643 pp.



CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2001098282	A1	20011227	WO 2001-JP5347	20010622
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2413429	A1	20011227	CA 2001-2413429	20010622
	AU 200174588	A	20020102	AU 2001-74588	20010622
	JP 2002080468	A	20020319	JP 2001-189417	20010622
	JP 2003064063	A	20030305	JP 2002-233086	20010622
	EP 1292585	A1	20030319	EP 2001-941174	20010622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011835	A	20030429	BR 2001-11835	20010622
	HU 2003001301	A2	20030828	HU 2003-1301	20010622
	US 2003078251	A1	20030424	US 2002-203524	20020809
	ZA 2002009055	A	20031107	ZA 2002-9055	20021107
	MX 2002PA12481	A	20030606	MX 2002-PA12481	20021216
	NO 2002006164	A	20021220	NO 2002-6164	20021220
FRAI	JP 2000-190253	A	20000623		
	JP 2001-189417	A3	20010622		
	WO 2001-JP5347	W	20010622		
OS	MARPAT 136:69829				
GI					




- AB Alkoxyphenyloxobenzoxazepineacetamides [I; R = (un)substituted 1-carboxyethyl, (un)substituted carboxyalkyl, sulfonylalkyl, (carboxycycloalkyl)alkyl, etc.; R1 = alkyl (un)substituted with alkanoyloxy or OH groups (if R = (un)substituted 1-carboxyethyl, alkyl, 4-carboxycyclohexylmethyl, or 4-carboxyphenylmethyl, then R1 must be substituted with a OH or alkanoyloxy group); R2 = lower alkyl; W = halogen] are prepared as squalene synthase inhibitors for the treatment of hyperlipidemia and the decrease of serum triglycerides and lipids. (3R, 4S)-I [R = Me(CH₂)₂SO₂; R1 = HOCH₂C(Me)₂CH₂; R2 = Me; W = Cl] (II) was prepared in 3 steps from hydroxyacid (III) by acetylation of the hydroxyl group with acetic anhydride, treatment of the acid with thionyl chloride in THF to generate the acid chloride in situ, and addition of the mixture to a solution of PrSO₂NH₂ in THF to provide the acetylated methoxyphenyloxobenzoxazepineacetamide I [R = PrSO₂; R1 = AcOCH₂C(Me)₂CH₂; R2 = Me; W = Cl]; hydrolysis of the acetoxy group with aqueous sodium hydroxide and ethanol provides II. Data for the inhibition of squalene synthase by I are given. Pharmaceutical compns. containing I [R = 3-(HO₂CCH₂CH₂)C₆H₄; R1 = HOCH₂CMe₂CH₂; R2 = Me; W = Cl] are specified.
- IT 383667-47-8P 383667-74-1P 383672-38-8P
383672-35-3P 383672-40-0P 383672-50-2P
383672-67-1P 383672-82-0P 383672-88-6P
383672-95-5P 383673-01-6P 383673-16-3P
383674-95-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediates; preparation of dialkoxyphenyloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents)
- RN 383667-47-8 CAPLUS
- CN 1H-Indole-2-carboxylic acid, 7-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



- RN 383667-74-1 CAPLUS
- CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-30-8 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-35-3 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-40-0 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-50-2 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-67-1 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-82-0 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-88-6 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-95-5 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-phenyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-01-6 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(4-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-16-3 CAPLUS

CN Acetic acid, [[5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-95-1 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 383653-40-5P 383657-22-5P 383657-72-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(title compds.; preparation of dialkoxyphenyloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents)

RN 383653-40-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[[3-(2-pyridinythio)propylsulfonyl]-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-22-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 7-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-72-5 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 383653-45-0P 383657-27-0P 383657-78-1P
 383660-26-2P 383660-32-0P 383660-38-6P
 383660-43-3P 383660-48-8P 383660-52-4P
 383660-57-9P 383660-62-6P 383660-67-1P
 383661-12-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(title compds.; preparation of dialkoxyphenyloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents)

RN 383653-45-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[[3-(2-pyridinylthio)propylsulfonyl]-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-27-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 7-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9C1) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-78-1 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-26-2 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-32-0 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-38-6 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-43-3 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-48-8 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-52-4 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-57-9 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-62-6 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-67-1 CAPLUS

CN Acetic acid, [[5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-12-9 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:565016 CAPLUS Full-text

DN 135:137529

TI Preparation of azepine derivatives as VLA-4 antagonists

IN Ikegami, Satoru; Inoguchi, Kiyoshi; Fukui, Hideto; Sumita, Yuji; Maruyama, Tatsuya; Watanuki, Mitsuru

PA Kaken Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001055121	A1	20010802	WO 2001-JP521	20010126
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2000-20358	A	20000128		
OS	MARPAT 135:137529				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R1 = H, alkyl, aryl; R2 = H, (CH3)3COCO; R3 = alkylene, divalent aromatic hydrocarbon derivs.; R4 = H, alkyl; X = aromatic hydrocarbon; heterocycle; m = 1, 2, 3; Y = N, O; Z = R8R7R6A1; A1 = CH2, SO2; R6 = alkylene, divalent arylalkane derivs.; R7 = CH2, CO; R8 = alkyl, arylalkyl] and salts are prepared Title compds. or salts of title compds. are used as the active ingredient in remedies having peroral absorbability and exhibiting VLA-4 antagonism. Thus, the title compound II was prepared and biol. tested for VLA-4 antagonism.

IT 351903-54-3P 351903-55-4P 352234-56-1P


352234-57-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azepine derivs. as VLA-4 antagonists)

RN 351903-54-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[[2-chloro-5-[[[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351903-55-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352234-56-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352234-57-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 351994-20-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of azepine derivs. as VLA-4 antagonists)

RN 351894-20-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, ethyl ester, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 351903-56-5P 351903-57-6P 351903-58-7P

351903-59-8P 351903-60-1P 351903-61-2P

352234-61-8P 352234-62-9P 352234-63-0P

352234-64-1P 352234-65-2P 352234-66-3P

352234-67-4P 352234-68-5P 352234-69-6P

352234-70-9P 352234-71-0P 352234-72-1P

352234-73-2P 352234-74-3P 352234-82-3P

352234-83-4P 352234-93-6P 352234-94-7P

352234-95-8P 352235-02-8P 352235-03-1P


352235-04-2P 352235-05-3P 352235-06-4P
 352235-07-5P 352235-08-6P 352235-09-7P
 352235-10-0P 352235-11-1P 352235-12-2P
 352235-13-3P 352235-14-4P 352235-15-5P
 352235-20-2P 352235-21-3P 352235-22-4P
 352235-23-5P 352235-24-6P 352235-25-7P
 352235-26-8P 352235-27-9P 352235-28-0P
 352235-29-1P 352235-30-4P 352235-31-5P
 352235-32-6P 352235-33-7P 352235-34-8P
 352235-35-9P 352235-64-4P 352235-65-5P
 352235-66-6P 352235-67-7P 352235-68-8P
 352235-72-4P 352236-61-4P 352236-63-6P
 352236-65-8P 352236-67-0P 352236-69-2P
 352236-71-6P 352236-73-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azepine derivs. as VLA-4 antagonists)

RN 351903-56-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl]-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351903-57-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl]-, (3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351903-58-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[(2S)-2-[[[3-methoxy-4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]-4-methylpentyl]-2-oxo-5-phenyl-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351903-59-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-[[3-[[[4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-, (3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351903-60-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[(2R)-2-[[[3-methoxy-4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]-4-methylpentyl]-2-oxo-5-phenyl-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351903-61-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[(2R)-2-[[[3-methoxy-4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]-4-methylpentyl]-2-oxo-5-phenyl-, (3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352234-61-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[4-[[[(2-methoxyphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 352234-62-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[3-[[[4-[[[(2-fluorophenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-

1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352234-63-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[[3-[[[4-[[[4-carboxyphenyl]amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352234-64-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[[3-[[[4-[[[3-methoxyphenyl]amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352234-65-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[3-methoxy-4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352234-66-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[4-[[[3-methylphenyl]amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352234-67-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[4-[4-
[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1-
oxobutyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX
NAME)


Relative stereochemistry.



RN 352234-68-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[5-[4-
[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1-
oxopentyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX
NAME)


Relative stereochemistry.



RN 352234-69-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[4-
[[[(2-methylphenyl)amino]carbonyl]amino]benzoyl]amino]phenyl]methyl]-2-oxo-
5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-70-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1-oxopropyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-71-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[4-[[[hydroxy(phenylmethyl)amino]carbonyl]amino]benzoyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-72-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1-oxo-3-phenylpropyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-73-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[1-[[[(2-methylphenyl)amino]carbonyl]-4-piperidiny]carbonyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-74-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[1-
 [[(2-methylphenyl)amino]carbonyl]-3-piperidinyl]carbonyl]amino]phenyl]meth
 yl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 352234-82-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-2-oxo-5-

phenyl-1-[[3-[[3-(3-pyridinylcarbonyl)benzoyl]amino]phenyl]methyl]-,
(3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-83-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-[[3-[[3-(2-pyridinylcarbonyl)benzoyl]amino]phenyl]methyl]-,
(3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-93-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[3-(1H-indol-5-ylcarbonyl)benzoyl]amino]phenyl]methyl]-2-oxo-5-phenyl-,
(3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-94-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-([3-([3-(1H-indol-2-ylcarbonyl)benzoyl]amino)phenyl)methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352234-95-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-([3-([3-(1H-indol-3-ylcarbonyl)benzoyl]amino)phenyl)methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-02-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-([3-([4-[(2-methoxyphenyl)acetyl]amino)phenyl]acetyl]amino)phenyl)methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-03-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[3-[[[4-[(2,6-dichlorobenzoyl)amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-04-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[3-[[[4-(benzoylamino)phenyl]acetyl]amino]phenyl]methyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-05-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[3-[[[4-[(2,6-dimethylbenzoyl)amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-06-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[3-[[[4-[(2,6-dimethoxybenzoyl)amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-07-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[3-[[[4-[(2-benzothiazolylcarbonyl)amino]phenyl]acetyl]amino]phenyl]methyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-08-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[[3-[[[4-(acetylamino)phenyl]acetyl]amino]phenyl]methyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-09-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[[3-[[[4-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]benzoyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-10-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[1-(2-naphthalenylcarbonyl)-4-piperidinyl]carbonyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-11-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-[[3-[[[1-(phenylsulfonyl)-4-piperidinyl]carbonyl]amino]phenyl]methyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-12-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-[[3-[[[1-(phenylsulfonyl)-3-piperidinyl]carbonyl]amino]phenyl]methyl]-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 352235-13-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-[[3-[[[4-[[[(1E)-2-phenylethenyl]sulfonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 352235-14-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[3-[[[(2E)-4-(3,4-dihydro-2(1H)-isoquinolinyl)-1,4-dioxo-2-butenyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 352235-15-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[3-[[[(2E)-1,4-dioxo-4-
[(1,2,3,4-tetrahydro-1-naphthalenyl)amino]-2-butenyl]amino]phenyl]methyl]-
1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 352235-20-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[[2-fluoro-5-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-21-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[[2-fluoro-5-[[[3-methoxy-4-[[[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-22-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-23-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[3-methoxy-4-[[[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-24-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[3-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]sulfonyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-25-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[4-[[[2-methylphenyl]amino]carbonyl]amino]phenyl]sulfonyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-26-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[[4-[[[hydroxy(phenylmethyl)amino]carbonyl]amino]benzoyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-27-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-chloro-5-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-1-oxo-3-phenylpropyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 352235-28-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[2-bromo-5-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-29-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-methoxy-5-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-30-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[2-(dimethylamino)-5-[[[3-methoxy-4-[[[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-31-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[5-[[[3-methoxy-4-[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]-2-(1-pyrrolidinyl)phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-32-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[4-chloro-3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-33-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[2-methyl-3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352235-34-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[[2-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl)methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)



Relative stereochemistry.



RN 352235-35-9 CAPLUS


CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[[2-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl)methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 352235-64-4 CAPLUS
 CN 4,1-Benzoxazepine-3-acetic acid, 1,2,3,5-tetrahydro-1-[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-5-phenyl-, (3S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352235-65-5 CAPLUS
 CN 4,1-Benzoxazepine-3-acetic acid, 1,2,3,5-tetrahydro-1-[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-2-oxo-

5-phenyl-, (3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352235-66-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[[3-[[[4-[[[4-carboxyphenyl]amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352235-67-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1-[[[3-[[[4-[[[4-carboxyphenyl]amino]carbonyl]amino]phenyl]acetyl]amino]phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-5-phenyl-, (3S,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352235-68-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl)methyl]-2-oxo-5-phenyl-, (3S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352235-72-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-[[3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]phenyl)methyl]-2-oxo-, (3S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352236-61-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[2-[[[4-
[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]ethyl]-2-oxo-5-
phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352236-63-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[3-[[[4-
[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]propyl]-2-oxo-5-
phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352236-65-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[4-[[[4-
[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]butyl]-2-oxo-5-
phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352236-67-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[[3-methoxy-4-[[[(phenylamino)carbonyl]amino]phenyl]acetyl]amino]cyclohexyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352236-69-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1,2,3,5-tetrahydro-1-[[1-[[3-methoxy-4-[[[(phenylamino)carbonyl]amino]phenyl]acetyl]-3-pyrrolidinyl]methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 352236-71-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1,2,3,5-tetrahydro-1-[(3R)-1-[[3-methoxy-

4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-3-piperidinyl)methyl]-2-oxo-5-phenyl-, (3S,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 352236-73-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 1,2,3,5-tetrahydro-1-[[[(3R)-1-[[[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-3-piperidinyl)methyl]-2-oxo-5-phenyl-, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:224390 CAPLUS [Full-text](#)

DN 134:252365

TI Preparation of oxazinobenzoxazepineacetates and analogs as squalene synthetase inhibitors

IN Hayward, Cheryl M.; Scully, Douglas A.

PA Pfizer Inc., USA

SO U.S., 44 pp.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----		-----	-----	-----
PI	US 6207664	B1	20010327	US 1999-441339	19991116
PRAI	US 1998-109939P	P	19981125		
OS	MARPAT 134:252365				
GI					



AB Title compds. [I; R = (un)substituted Ph or -naphthyl; R1,R2 = H, halo, alkyl, alkoxy, etc.; R3 = CO2H, alkoxycarbonyl, CONH2, etc.; R4 = alk(en)yl, cycloalkylmethyl, Ph, etc.; Z = O, S, CH2; Z1 = O or S] were prepared (no data). Thus, (1R,7S,9R)-I [R = C6H3(OMe)2-2,3, R1 = 5-Me, R2 = H, R3 = CO2H, R4 = CMe3, Z1 = Z2 = O] was prepared starting from 3-tert-butyl-7-methyl-3,4-dihydro-2H-1,4-benzoxazine and 2,3-(MeO)2C6H3CHO.


IT 331635-30-4P 331635-35-9P 331635-38-2P
331635-44-0P 331635-50-8P 331635-51-9P
331635-52-0P 331635-54-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazinobenzoxazepineacetates and analogs as squalene synthetase inhibitors)

RN 331635-30-4 CAPLUS

CN 3-Pyrrolidinamine, 1-[[[(3R,6R,8S)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-8H-1,4-oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-35-9 CAPLUS

CN 3-Pyrrolidinamine, 1-[[[(3R,6R,8S)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-8H-1,4-oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-38-2 CAPLUS

CN 8H-1,4-Oxazino[2,3,4-jk][4,1]benzoxazepine-6-acetamide, N-(2-aminoethyl)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-, (3R,6R,8S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 331635-44-0 CAPLUS

CN Benzeneacetic acid, α -[[[3-[[[(3R,6R,8S)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-8H-1,4-

oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]methylamino]propyl]methylamino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-50-8 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[[(3R,6R,8S)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-8H-1,4-oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-51-9 CAPLUS

CN 1H-Indole-2-carboxylic acid, 4-[[[(3R,6R,8S)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-8H-1,4-oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-52-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 6-[[[(3R,6R,8S)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-8H-1,4-oxazino[2,3,4-jk][4,1]benzoxazepin-6-yl]acetyl]amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 331635-54-2 CAPLUS

CN 8H-1,4-Oxazino[2,3,4-jk][4,1]benzoxazepine-6-acetamide, N-(6-aminoethyl)-8-(2,3-dimethoxyphenyl)-3-(1,1-dimethylethyl)-2,3,5,6-tetrahydro-10-methyl-5-oxo-, (3R,6R,8S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:709062 CAPLUS Full-text

DN 129:330745

TI Preparation of 4,1-benzoxazepines as somatostatin agonists.

IN Mabuchi, Hiroshi; Suzuki, Nobuhiro; Miki, Takashi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 3/77 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9847882	A1	19981029	WO 1998-JP1797	19980420
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2285664	A1	19981029	CA 1998-2285664	19980420
	AU 9868545	A	19981113	AU 1998-68545	19980420
	JP 11209356	A	19990803	JP 1998-109869	19980420
	EP 979227	A1	20000216	EP 1998-914096	19980420
	EP 979227	B1	20051116		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 309993	T	20051215	AT 1998-914096	19980420
	US 6352982	B1	20020305	US 1999-403066	19991014
PRAI	JP 1997-103138	A	19970421		
	JP 1997-319545	A	19971120		
	WO 1998-JP1797	W	19980420		
OS	MARPAT 129:330745				
GI					



I

AB Title compds. [I; A = atoms to form a (substituted) (hetero)aromatic ring; B = (substituted) (hetero)aromatic ring; Z = (substituted) cyclic group, linear hydrocarbon group; R1 = H, (substituted) hydrocarbyl, heterocyclyl; R2 = (substituted) amino; D = bond, (substituted) divalent hydrocarbyl; E = bond, CON(Ra), N(Ra)CO, N(Rb)CON(Rc), N(Rd)CO2, N(Re)SO2, CO2, N(Rf), O, S, SO, SO2, N-carboxypiperidin-4-yl, N-carboxypiperazin-4-yl; Ra-Rf = H, (substituted) hydrocarbyl; G = bond, divalent (substituted) hydrocarbyl; L = divalent group; R2B = (substituted) non-aromatic condensed N-heterocyclyl; X = H2, O, S; dotted line = optional double bond; Y = N when dotted line = double bond, or O, NR4, S, SO, SO2; R4 = H, (substituted) hydrocarbyl, acyl; when dotted line = single bond], were prepared Thus, 3,5-trans-N-(2-fluorobenzyl)-5-(3-

aminomethylphenyl)-1-(4-biphenylmethyl)- 7-chloro-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide hydrochloride (multistep preparation given) at 3 mg/kg i.p. in rats reduced plasma growth hormone concns. from 92 ng/mL (controls) to 11.2 ng/mL.

IT 215185-08-3P 215185-09-4P 215185-12-9P
 215185-13-0P 215185-14-1P 215185-17-4P
 215185-18-5P 215185-23-2P 215185-27-6P
 215185-28-7P 215185-29-8P 215185-30-1P
 215185-31-2P 215185-32-3P 215185-33-4P
 215185-34-5P 215185-35-6P 215185-36-7P
 215185-37-8P 215185-38-9P 215185-39-0P
 215185-40-3P 215185-41-4P 215185-42-5P
 215185-47-0P 215185-48-1P 215185-49-2P
 215185-50-5P 215185-51-6P 215185-52-7P
 215185-53-8P 215185-54-9P 215185-56-1P
 215185-59-4P 215185-60-7P 215185-63-0P
 215185-64-1P 215185-65-2P 215185-66-3P
 215185-71-0P 215185-72-1P 215185-73-2P
 215185-74-3P 215185-75-4P 215185-76-5P
 215185-77-6P 215185-78-7P 215185-79-8P
 215185-80-1P 215185-81-2P 215185-82-3P
 215185-83-4P 215185-84-5P 215185-85-6P
 215185-86-7P 215185-87-8P 215185-88-9P
 215185-89-0P 215185-90-3P 215185-91-4P
 215185-92-5P 215185-93-6P 215185-94-7P
 215185-96-9P 215185-99-2P 215186-02-0P
 215186-05-3P 215186-06-4P 215186-08-6P
 215186-11-1P 215186-12-2P 215186-14-4P
 215186-16-6P 215186-22-4P 215186-24-6P
 215186-25-7P 215186-26-8P 215186-29-1P
 215186-30-4P 215186-33-7P 215186-34-8P
 215186-38-2P 215186-41-7P 215186-42-8P
 215186-43-9P 215186-49-5P 215186-50-8P
 215186-53-1P 215186-54-2P 215186-55-3P
 215186-56-4P 215186-62-2P 215186-66-6P
 215186-68-8P 215186-70-2P 215186-72-4P
 215186-74-6P 215186-76-8P 215186-78-0P
 215186-80-4P 215186-82-6P 215186-83-7P
 215186-84-8P 215186-85-9P 215186-86-0P
 215186-87-1P 215186-88-2P 215186-89-3P
 215186-90-6P 215186-91-7P 215186-92-8P
 215186-93-9P 215186-94-0P 215186-95-1P
 215186-96-2P 215186-97-3P 215186-98-4P
 215187-00-1P 215187-02-3P 215187-05-6P
 215187-07-8P 215187-09-0P 215187-11-4P
 215187-13-6P 215187-14-7P 215187-16-9P
 215187-18-1P 215187-19-2P 215187-23-8P
 215187-24-9P 215187-27-2P 215187-30-7P
 215187-32-9P 215187-34-1P 215187-38-5P
 215187-40-9P 215187-44-3P 215187-45-4P
 215187-48-7P 215187-49-8P 215187-55-6P
 215187-56-7P 215187-57-6P 215187-58-9P
 215187-61-4P 215187-62-5P 215187-64-7P
 215187-65-8P 215187-67-0P 215187-68-1P
 215187-69-2P 215187-70-5P 215187-75-0P
 215187-76-1P 215187-77-2P 215187-78-3P
 215187-81-6P 215187-82-9P 215187-88-5P
 215187-89-6P 215187-90-9P 215187-91-0P
 215187-92-1P 215187-93-2P 215187-94-3P
 215187-95-4P 215187-96-5P 215187-97-6P

215187-96-7P 215187-99-8P 215188-00-4P
 215188-01-5P 215188-02-6P 215188-03-7P
 215188-04-8P 215188-05-9P 215188-08-2P
 215188-09-3P 215188-16-2P 215188-17-3P
 215188-19-5P 215188-26-8P 215188-21-9P
 215188-22-0P 215188-25-3P 215188-26-4P
 215188-30-0P 215188-31-1P 215188-33-3P
 215188-34-4P 215188-38-8P 215188-39-5P
 215188-42-4P 215188-43-5P 215188-45-7P
 215188-46-8P 215188-49-1P 215188-50-4P
 215188-52-6P 215188-53-7P 215188-55-9P
 215188-56-0P 215188-60-6P 215188-82-2P
 215188-87-7P 215188-88-8P 215188-89-9P
 215188-90-2P 215188-95-7P 215188-96-6P
 215188-97-9P 215188-98-0P 215189-05-2P
 215189-06-3P 215189-11-0P 215189-12-1P
 215189-13-2P 215189-14-3P 215189-20-1P
 215189-21-2P 215189-22-3P 215189-23-4P
 215189-24-5P 215189-25-6P 215189-26-7P
 215189-27-8P 215189-28-9P 215189-29-0P
 215189-30-3P 215189-31-4P 215189-37-0P
 215189-38-1P 215189-39-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4,1-benzoxazepines as somatostatin agonists)

RN 215185-08-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-09-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5S)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-12-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-13-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-14-1 CAPLUS

CN Carbamic acid, [{3-[(3R,5R)-1-[(1,1'-biphenyl)-4-ylmethyl]-7-chloro-3-[(2-(2-fluorophenyl)methyl)amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-17-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-[(1,1'-biphenyl)-4-ylmethyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-18-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-23-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-7-(3-phenylpropoxy)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-27-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[2-(2-fluorophenyl)ethyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-28-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-chlorophenyl)methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-29-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(2-methoxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-30-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2,4-difluorophenyl)methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-31-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N-[[3,5-bis(trifluoromethyl)phenyl)methyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-32-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(phenylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-33-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-N-methyl-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-34-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-pyridinylmethyl)-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 215185-35-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-(2-furanylmethyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-36-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-thienylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-37-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[[2-(fluoromethyl)phenyl]methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-38-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2,6-difluorophenyl)methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-39-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-(1H-indol-3-ylmethyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-40-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-(cyclohexylmethyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-41-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 215185-42-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 215185-47-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 215185-48-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


● HCl

RN 215185-49-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-N-[[3,4,5-trimethoxyphenyl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 215185-50-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-(diphenylmethyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-51-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N-([1,1'-biphenyl]-2-ylmethyl)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-

tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-52-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N,1-bis([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-53-8 CAPLUS

CN Benzoic acid, 4-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, ethyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




HCl

RN 215185-54-9 CAPLUS

CN 4,1-Benzoxazine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-7-(3-phenylpropoxy)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 215185-56-1 CAPLUS
 CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[[[(2-fluorophenyl)acetyl]amino]methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.



RN 215185-59-4 CAPLUS
 CN Benzeneacetamide, N-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-2-fluoro-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-60-7 CAPLUS
 CN Carbamic acid, [[3-[(3R,5R)-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-

oxoethyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-7-(2-methylpropoxy)-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-63-0 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[[[(2-fluorophenyl)methyl]amino]carbonyl]amino]methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-64-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-7-(2-methylpropoxy)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-65-2 CAPLUS

CN Urea, N-[[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-N'-[(2-fluorophenyl)methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-66-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[(phenylmethyl)amino]methyl]phenyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-71-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-(1-piperidinylmethyl)phenyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-72-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[(methylamino)methyl]phenyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-73-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[(dimethylamino)methyl]phenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-74-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(3-phenylpropyl)-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-75-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(cyclohexylmethyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-76-5 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(2-phenylethyl)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-77-6 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(3-thienylmethyl)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-78-7 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[(4-phenoxypheyl)methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-79-8 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(3-methoxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-80-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2-ethylbutyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-81-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-pentyl-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215185-82-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-(2-naphthalenylmethyl)-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215185-83-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-(2-[1,1'-biphenyl]-4-ylethyl)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-84-5 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-2-ylmethyl)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-85-6 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-(1H-indol-3-ylmethyl)-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 215185-86-7 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 215185-87-8 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-nitrophenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)

(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215185-88-9 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(1-methyl-1H-indol-3-yl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215185-89-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(3-phenylpropyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-90-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(cyclohexylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-91-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(2-phenylethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-92-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[(3-thienylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-93-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[(4-phenoxyphenyl)methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-94-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(3-methoxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-96-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2-ethylbutyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215185-99-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-pentyl-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215186-02-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(2-naphthalenylmethyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-05-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-(2-[1,1'-biphenyl]-4-ylethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-06-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-2-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-08-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(1H-indol-3-ylmethyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-11-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl)methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-12-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-nitrophenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-14-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(1-methyl-1H-indol-3-yl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215186-16-6 CAPLUS

CN Carbamic acid, [[2-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215186-22-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[2-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-24-6 CAPLUS

CN Carbamic acid, [[2-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215186-25-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[2-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-26-8 CAPLUS

CN Carbamic acid, [3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-29-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-(3-aminophenyl)-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-30-4 CAPLUS

CN Carbamic acid, [[4-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215186-33-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215186-34-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(2-aminoethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215186-38-2 CAPLUS


CN Carbamic acid, [2-[4-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]ethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215186-41-7 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(2-aminoethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 215186-42-8 CAPLUS
 CN Carbamic acid, [[4-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.



RN 215186-43-9 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215186-49-5 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-50-8 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5S)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-53-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-54-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-1-
 ([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-
 tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-55-3 CAPLUS

CN Carbamic acid, [(3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-
 [(4-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-
 benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



RN 215186-56-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(4-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-62-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[[[(2-fluorophenyl)methyl]amino]methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-66-6 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215186-68-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-70-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[[4-(acetyloxy)phenyl]methyl]-5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-72-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(3-phenoxypropoxy)phenyl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215186-74-6 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 4-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-chloro-3-[2-[[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]methyl]phenyl ester, monohydrochloride, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

||

● HCl


RN 215186-76-8 CAPLUS
 CN Acetic acid, [4-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]methyl]phenoxy]-, ethyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215186-78-0 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-[[4-[2-(dimethylamino)-2-oxoethoxy]phenyl]methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-80-4 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 1-[[4-[2-(acetyloxy)ethoxy]phenyl]methyl]-5-

[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-82-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[[4-(2-hydroxyethoxy)phenyl]methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-83-7 CAPLUS

CN Acetic acid, [4-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]methyl]phenoxy]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-84-8 CAPLUS

CN Acetic acid, [4-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]methyl]phenoxy]-, methyl ester, monohydrochloride, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215186-85-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215186-86-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[(methylsulfonyl)amino]methyl]phenyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215186-87-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[trifluoroacetyl]amino]methyl]phenyl]-, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-88-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[[2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-89-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[[[(methylamino)carbonyl]amino]methyl]phenyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215186-90-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[(acetylamino)methyl]phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 215186-91-7 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-[(4-aminophenyl)methyl]-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


NH₂

RN 215186-92-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[[4-(acetaminophenyl)methyl]-5-[3-

(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215186-93-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[[4-[(methylsulfonyl)amino]phenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






● HCl


RN 215186-94-0 CAPLUS
 CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-[[4-(dimethylamino)phenyl]methyl]-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.



RN 215186-95-1 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-[[4-(dimethylamino)phenyl]methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-96-2 CAPLUS

CN Carbamic acid, [3-[[[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]amino]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215186-97-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[[[(3-aminopropyl)amino]methyl]phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 215186-98-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-[[(aminoacetyl)amino]methyl]phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-00-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[(4-piperidinylcarbonyl)amino]methyl]phenyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-02-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[2-(3-aminopropoxy)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-05-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-07-8 CAPLUS

CN Carbamic acid, [(3-[(3R,5R)-1-[(1,1'-biphenyl)-4-ylmethyl]-7-chloro-3-[2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-09-0 CAPLUS

CN Piperazine, 1-[(3R,5R)-5-[3-(aminomethyl)phenyl]-1-[(1,1'-biphenyl)-4-ylmethyl]-7-chloro-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-(4-fluorophenyl)-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-11-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-3-[2-oxo-2-(4-phenyl-1-piperidinyl)ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215187-13-6 CAPLUS

CN Piperidine, 1-[[(3R,5R)-5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-phenyl-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-14-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(3,3-dimethylbutyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[(triphenylmethyl)amino]methyl]phenyl]-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215187-16-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(3,3-dimethylbutyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[3-[[(triphenylmethyl)amino]methyl]phenyl]-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215187-18-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(3,3-dimethylbutyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-19-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-[[4-[(acetyloxy)methyl]phenyl]methyl]-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




AcO

RN 215187-23-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[[4-[(acetyloxy)methyl]phenyl]methyl]-5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215187-24-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-

fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[[4-(hydroxymethyl)phenyl]methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215187-27-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-30-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-32-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-34-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-7-methoxy-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-38-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-7-methoxy-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-40-9 CAPLUS


CN Carbamic acid, [[3-[(3R,5R)-1-[(1,1'-biphenyl)-4-ylmethyl]-8-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215187-44-3 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-8-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215187-45-4 CAPLUS
 CN Carbamic acid, [1-[4-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215187-48-7 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(1-amino-1-methylethyl)phenyl]-1-
 ([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-
 tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-49-8 CAPLUS


CN Carbamic acid, [1-[3-[(3R,5R)-7-chloro-3-[2-[[2-(4-(phenylmethoxy)phenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl)methyl]-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215187-55-6 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






● HCl

RN 215187-56-7 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-7-chloro-3-[2-[[2-(4-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-57-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-58-9 CAPLUS

CN Carbamic acid, [2-[2-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]ethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-61-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[2-(2-aminoethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215187-62-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[(3R,5R)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]methyl]-, phenylmethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 215187-64-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-

chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]methyl]-, phenylmethyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-65-8 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[3-(phenylmethoxy)phenyl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-67-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[3-(phenylmethoxy)phenyl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-68-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(3-hydroxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215187-69-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(3-hydroxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-70-5 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[2-(4-hydroxyphenyl)ethyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215187-75-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[2-(4-hydroxyphenyl)ethyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215187-76-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-methoxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215187-77-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-methoxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-78-3 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-methoxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-81-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-methoxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-82-9 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-hydroxy-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215187-88-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-7-hydroxy-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-89-6 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-(3-chloropropoxy)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-90-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-(3-chloropropoxy)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-91-0 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-(2-oxo-2-phenylethoxy)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215187-92-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-7-(2-oxo-2-phenylethoxy)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 215187-93-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-(2-hydroxyethoxy)-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215187-94-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-7-(2-hydroxyethoxy)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


● HCl

RN 215187-95-4 CAPLUS

CN Acetic acid, [(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-5-[3-[[[(1,1-

dimethylethoxy)carbonyl]amino)methyl]phenyl]-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-7-yl]oxy]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-96-5 CAPLUS

CN Acetic acid, [[[(3R,5R)-5-[3-(aminomethyl)phenyl]-1-[(1,1'-biphenyl)-4-ylmethyl]-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-7-yl]oxy]-, methyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




PAGE 1-A

● HCl

RN 215187-97-6 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-(phenylmethoxy)-9C1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (4I) (CA INDEX NAME)


Relative stereochemistry.



RN 215187-98-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-7-(phenylmethoxy)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




HCl

RN 215187-99-8 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-[(1,1'-biphenyl]-4-ylmethyl)-7-(cyclohexylmethoxy)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-00-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-(cyclohexylmethoxy)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 215188-01-5 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-[3-(1H-imidazol-1-yl)propoxy]-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-02-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-7-[3-(1H-imidazol-1-yl)propoxy]-2-oxo-, dihydrochloride, (3R,5R)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 215188-03-7 CAPLUS

CN Acetic acid, [(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-5-[3-[[[(1,1-

dimethylethoxy)carbonyl]amino)methyl]phenyl]-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-7-yl]oxy]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-04-8 CAPLUS

CN Acetic acid, [(3R,5R)-5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-7-yl]oxy]-, phenylmethyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




● HCl

RN 215188-05-9 CAPLUS

CN Carbamic acid, [2-[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]ethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-08-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(2-aminoethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

CN Carbamic acid, [1-[3-[(3R,5R)-1-[(1,1'-biphenyl)-4-ylmethyl]-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-(3-phenylpropoxy)-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Chemical structure of compound 10, a macrocyclic compound. The structure features a 12-membered macrocycle with two amide bonds and two ether linkages. Substituents include a tert-butoxycarbonyl group, a 4-methoxyphenyl group, a 4-phenylbenzyl group, and a 3-iodobenzyl group. The macrocycle is labeled with 'R' at two positions.

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-1-
 ([1,1'-biphenyl]-4-ylmethyl)-N-(2-fluorophenyl)methyl-1,2,3,5-tetrahydro-
 2-oxo-7-(3-phenylpropoxy)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA
 INDEX NAME)


PAGE 1-A

● HCl

RN 215188-17-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4'-(phenylmethoxy)[1,1'-biphenyl]-4-yl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-19-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4'-(phenylmethoxy)[1,1'-biphenyl]-4-yl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




● HCl

RN 215188-20-8 CAPLUS


CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4'-hydroxy[1,1'-biphenyl]-4-yl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215188-21-9 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4'-hydroxy[1,1'-biphenyl]-4-yl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215188-22-0 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-[(4-fluorophenyl)methyl]-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215188-25-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1-[(4-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-26-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[3-(4-hydroxyphenyl)propyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-30-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[3-(4-hydroxyphenyl)propyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215188-31-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-[(1,1'-biphenyl)-4-ylmethyl]-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-[3-(4-hydroxyphenyl)propoxy]-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-33-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-7-[3-(4-hydroxyphenyl)propoxy]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


● HCl

RN 215188-34-4 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-1-[[4-(acetylamino)phenyl]methyl]-7-chloro-3-

[2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-38-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[[4-(acetylamino)phenyl]methyl]-5-[3-(1-amino-1-methylethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-39-9 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-

benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-42-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-1-
([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-
2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-43-5 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-7-chloro-1-[[4-(diethylamino)phenyl]methyl]-
3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-
4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester,

rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

Net₂

RN 215188-45-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-7-chloro-1-[[4-(diethylamino)phenyl]methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, dihydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl


RN 215188-46-8 CAPLUS

CN Carbamic acid, [[3-[7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(3-phenyl-2-propenyl)-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 215188-49-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(3-phenyl-2-propenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 215188-50-4 CAPLUS

CN Carbamic acid, [4-[2-[(3R,5R)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]ethyl]phenyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-52-6 CAPLUS

CN Carbamic acid, [4-[2-[(3R,5R)-5-[3-(aminomethyl)phenyl]-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]ethyl]phenyl]-, phenylmethyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-53-7 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1-(2-furanylmethyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-55-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1-(2-furanylmethyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 215188-56-0 CAPLUS
 CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-(5-thiazolylmethyl)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.




RN 215188-60-6 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-(5-thiazolylmethyl)-, (3R,5R)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 215188-59-3
 CME C29 H26 Cl F N4 O3 S

Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 215188-82-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-[[3,4-bis(phenylmethoxy)phenyl]methyl]-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 215188-87-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-[[3,4-bis(phenylmethoxy)phenyl]methyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-88-8 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-1-[(3,4-dihydroxyphenyl)methyl]-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-89-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-[(3,4-dihydroxyphenyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-90-2 CAPLUS


CN Carbamic acid, [[4-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215188-95-7 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 215188-96-8 CAPLUS
 CN Carbamic acid, [[4-[(3R,5R)-7-chloro-3-[2-[[2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.



RN 215188-97-9 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215188-98-0 CAPLUS

CN Carbamic acid, [[3-[(3R,5S)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-4-methoxyphenyl)methyl]-, 1,1-dimethylethyl ester, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-05-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[5-(aminomethyl)-2-methoxyphenyl]-1-
 ([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-
 tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-06-3 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-
 2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[2-(phenylmethoxy)phenyl]methyl]-
 4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



RN 215189-11-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[[2-(phenylmethoxy)phenyl]methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-12-1 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-[(2-hydroxyphenyl)methyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-13-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(2-hydroxyphenyl)methyl]-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-14-3 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 5-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-3,4-dihydro-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-20-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5- (1,2,3,4-tetrahydro-5-isoquinolinyl)-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-21-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-3-[(2-[(1-methylethyl)amino]-2-oxoethyl)-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-22-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-N-(1-methylethyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 215189-23-4 CAPLUS

CN Carbamic acid, [[3-((3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-3-[2-oxo-2-(1-pyrrolidinyl)ethyl]-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 215189-24-5 CAPLUS

CN Pyrrolidine, 1-[(3R,5R)-5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-25-6 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-3-[2-[(2-methoxyphenyl)amino]-2-oxoethyl]-2-oxo-4,1-benzoxazepin-5-yl]phenyl)methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-26-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-N-(2-methoxyphenyl)-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-27-8 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-3-[2-(cyclohexylamino)-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-28-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-cyclohexyl-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-29-0 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-3-[2-oxo-2-(2-thiazolylamino)ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-30-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-N-2-thiazolyl-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-31-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(trifluoromethyl)phenyl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-37-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 215189-38-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-(2-[1,1'-biphenyl]-4-ylethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-

tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 215189-39-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A

J_h

IT 215189-41-6P 215189-42-7P 215189-43-8P
215189-44-9P 215189-45-0P 215189-47-2P


215189-46-3P 215189-49-4P 215189-50-7P
215189-56-3P 215259-94-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4,1-benzoxazepines as somatostatin agonists)

RN 215189-41-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(1-amino-1-methylethyl)phenyl]-1-
([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-
tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-42-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[[4-(acetamino)phenyl]methyl]-5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-
tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-43-8 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[[4-[(methylsulfonyl)amino]phenyl)methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215189-44-9 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-([1,1'-biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-45-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-7-methoxy-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-47-2 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(1-amino-1-methylethyl)phenyl]-1-[(1,1'-biphenyl)-4-ylmethyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 215189-48-3 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[2-(4-hydroxyphenyl)ethyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-49-4 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-1-[(1,1'-

biphenyl]-4-ylmethyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-7-hydroxy-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-50-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-5-[(1,2,3,4-tetrahydro-5-isoquinolinyl)-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215189-56-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215299-94-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).





IT 215189-52-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 4,1-benzoxazepines as somatostatin agonists)

RN 215189-52-9 CAPLUS

CN Acetic acid, [4-[[[(3R,5R)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-4,1-benzoxazepin-1(5H)-yl]methyl]phenoxy]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 215185-26-5P 215185-43-6P 215185-44-7P
 215185-45-8P 215185-57-2P 215185-58-3P
 215185-62-9P 215187-36-3P 215187-63-6P
 215187-74-9P 215187-87-4P 215188-14-0P
 215188-15-1P 215188-29-7P 215188-32-2P
 215188-35-5P 215188-36-6P 215188-37-7P
 215188-44-6P 215188-51-5P 215188-57-1P
 215188-58-2P 215189-36-9P 215189-54-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4,1-benzoxazepines as somatostatin agonists)

RN 215185-26-5 CAPLUS


CN Carbamic acid, [[3-[(3R,5R)-3-[2-[[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-7-(3-phenylpropoxy)-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215185-43-6 CAPLUS
 CN L-Leucine, N-[[[(3R,5R)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215185-44-7 CAPLUS
 CN L-Leucine, N-[[[(3S,5S)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 215185-45-8 CAPLUS

CN L-Leucine, N-[[[(3S,5S)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 215185-57-2 CAPLUS


CN Carbamic acid, [[[(3R,5R)-7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, 9H-fluoren-9-ylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 215185-58-3 CAPLUS
 CN Carbamic acid, [[3-[(3R,5R)-3-(aminomethyl)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215185-62-9 CAPLUS
 CN Carbamic acid, [[3-[(3R,5R)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-(2-methylpropoxy)-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 215187-36-3 CAPLUS

CN Carbamic acid, [{3-[(3R,5R)-3-[2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-methoxy-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





PAGE 2-A



RN 215187-63-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1,2,3,5-tetrahydro-2-oxo-1-[[1-[(phenylmethoxy)carbonyl]-4-piperidinyl]methyl]-, ethyl ester, (3R,5R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 215187-74-9 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[2-[4-(phenylmethoxy)phenyl]ethyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 215187-87-4 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-[(tetrahydro-2H-pyran-2-yl)oxy]-4,1-benzoxazepin-5-yl]phenyl]methyl]-,

1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-14-0 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-[(tetrahydro-2H-pyran-2-yl)oxy]-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-15-1 CAPLUS

CN Carbamic acid, [1-[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-[(tetrahydro-2H-pyran-2-yl)oxy]-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-7-hydroxy-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-29-7 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-1-[3-[4-(phenylmethoxy)phenyl]propyl]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215188-32-2 CAPLUS

CN Carbamic acid, [[3-[(3R,5R)-1-([1,1'-biphenyl]-4-ylmethyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-7-[3-[4-(phenylmethoxy)phenyl]propoxy]-4,1-benzoxazepin-5-yl]phenyl]methyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 215188-35-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[1-[(1,1-dimethylethoxy)carbonyl]amino]-1-methylethyl]phenyl]-1,2,3,5-tetrahydro-1-[(4-nitrophenyl)methyl]-2-oxo-, ethyl ester, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

RN 215188-36-6 CAPLUS
 CN 4,1-Benzoxazepine-3-acetic acid, 1-[(4-aminophenyl)methyl]-7-chloro-5-[3-[1-[[1,1-dimethylethoxy)carbonyl]amino]-1-methylethyl]phenyl]-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 215188-37-7 CAPLUS
 CN Carbamic acid, [1-[3-[(3R,5R)-1-[(4-aminophenyl)methyl]-7-chloro-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 215188-44-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-1-[[4-(diethylamino)phenyl]methyl]-5-[3-[1-[(1,1-dimethylethoxy)carbonyl]amino]-1-methylethyl]phenyl]-1,2,3,5-tetrahydro-2-oxo-, ethyl ester, (3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 215188-51-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1,2,3,5-tetrahydro-2-oxo-1-[2-[4-[(phenylmethoxy)carbonyl]amino]phenyl]ethyl]-, ethyl ester,


(3R,5R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 215188-57-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-(((1,1-dimethylethoxy)carbonyl)amino)methyl]phenyl]-1,2,3,5-tetrahydro-2-oxo-1-(5-thiazolylmethyl)-, ethyl ester (CA INDEX NAME)



RN 215188-58-2 CAPLUS


CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-[3-(((1,1-dimethylethoxy)carbonyl)amino)methyl]phenyl]-1,2,3,5-tetrahydro-2-oxo-1-(5-thiazolylmethyl)- (CA INDEX NAME)



RN 215189-36-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(aminomethyl)phenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-1-[(4-(trifluoromethyl)phenyl)methyl]-, monohydrochloride, (3R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 215189-54-1 CAPLUS

CN Carbamic acid, [2-[3-[(3R,5R)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]phenyl]ethyl]-, 9H-fluoren-9-ylmethyl ester, rel- (9CI)
(CA INDEX NAME)



Relative stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1998:180583 CAPLUS Full-text
 DN 128:230397
 TI Preparation of 4,1-benzoxazepin-2-one derivatives and their uses
 IN Yukimasa, Hidefumi; Tozawa, Ryuichi; Kori, Masakuni; Kitano, Kazuaki;
 Sugiyama, Yasuo
 PA Takeda Chemical Industries, Ltd., Japan
 SO U.S., 105 pp., Cont.-in-part of U.S. Ser. No. 195,131, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5726306	A	19980310	US 1994-338163	19941109
	US 5885979	A	19990323	US 1997-852292	19970507
PRAI	JP 1992-99541	A	19920420		
	JP 1992-339947	A	19921221		
	US 1993-49455	B1	19930420		
	US 1994-195131	B2	19940209		
	JP 1994-244136	A	19941007		
	US 1994-338163	A3	19941109		
OS	MARPAT 128:230397				
GI					



AB Title compds. I (R = halogen; R1 = H, benzyl, alkyl, alkynyl, etc.; R2 = H, alkyl, Ph, heterocyclic, etc.; R3 = H, alkyl, Ph, heterocyclic, etc.; X = bond, spacer with chain length of 1-7 atoms; Y = carboxyl, alkoxy carbonyl, hydroxyl, amino group, Ph, carbamoyl group, etc.) and salts are prepared from condensation of II with 5-oxo-tetrahydro-2-furancarbonyl chloride and ClCO(Z)nCOOR4 ((Z)n = (CH2)3, CHCl(CH2)2, trans-CH:CH, etc.; R4 = H, Et, etc.). Title compds. I are useful for inhibiting squalene synthetase and fungal growth, and which are useful for treating or preventing hyperlipidemia in oral tablets or injections.

IT 152910-60-6P 152910-62-6P 152910-64-0P
 152910-66-2P 204505-84-0P 204505-91-9P
 204505-93-1P 204506-56-9P 204505-65-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)

(preparation of benzoxazepinone derivs. and their uses)

RN 152910-60-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[3-(1H-tetrazol-5-yl)phenyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-62-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[4-(1H-tetrazol-5-yl)phenyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-64-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(1-methylethyl)-2-oxo-N-(1H-tetrazol-5-ylmethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-66-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-N-(1H-tetrazol-5-ylmethyl)-, trans-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 204505-84-0 CAPLUS

CN L-Tryptophan, N-[1-oxo-3-[1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]propyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 204505-91-9 CAPLUS

CN L-Tryptophan, N-[1-oxo-3-[1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 204505-93-1 CAPLUS

CN L-Tryptophan, N-[3-(7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl)-1-oxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 204506-56-9 CAPLUS

CN L-Tryptophan, N-[3-(7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-3-yl)acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204585-65-9 CAPLUS

CN L-Tryptophan, N-[3-(7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 152908-11-7P 152908-33-3P 152908-55-9P
 152908-56-0P 152911-35-8P 204505-94-2P
 204505-95-3P 204506-04-7P 204585-56-8P
 204585-57-9P 204585-58-0P 204585-66-0P
 204586-80-1P 204586-81-2P 204586-82-3P
 204586-83-4P 204586-85-6P 204586-88-9P
 204586-89-0P 204587-06-6P 204717-30-6P
 204717-32-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzoxazepinone derivs. and their uses)

RN 152908-11-7 CAPLUS

CN Glycine, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-N-(1H-indol-3-ylmethyl)-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152908-33-3 CAPLUS

CN Glycine, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-N-(1H-indol-3-ylmethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152908-55-9 CAPLUS

CN Glycine, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]methyl]amino]carbonyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152908-56-0 CAPLUS

CN Glycine, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]methyl]amino]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 152911-35-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-

dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(1H-tetrazol-5-ylmethyl)-,
trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 204505-94-2 CAPLUS

CN L-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]-1-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 204505-95-3 CAPLUS

CN D-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]-1-oxopropyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 204506-04-7 CAPLUS

CN D-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]-1-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 204585-56-8 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204585-57-9 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204585-58-0 CAPLUS

CN D-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204585-66-0 CAPLUS


CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 204586-80-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, hydrazide (CA INDEX NAME)




RN 204586-81-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, 2,2-dimethylhydrazide (CA INDEX NAME)




RN 204586-82-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 204586-83-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(3-amino-3-oxopropyl)-7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(1-methylethyl)-2-oxo- (CA INDEX NAME)



RN 204586-85-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-[[4-(dimethylamino)phenyl]methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo- (CA INDEX NAME)




RN 204586-88-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-[3-(dimethylamino)propyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 204586-87-8

CMF C27 H35 Cl2 N3 O3



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 204586-89-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 204587-08-6 CAPLUS


CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, butanoate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 204585-56-8

CMF C29 H25 Cl2 N3 O5


Absolute stereochemistry.



CM 2

CRN 107-92-6


CMF C4 H8 O2



RN 204717-30-6 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 204717-32-8 CAPLUS
 CN D-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, butanoate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 204717-31-7

CMF C36 H31 Cl2 N3 O5


Absolute stereochemistry.



CM 2

CRN 107-92-6


CMF C4 H8 O2



IT 152910-61-7P 152910-63-9P 152910-65-1P
 152910-67-3P 152911-36-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzoxazepinone derivs. and their uses)
 RN 152910-61-7 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(3-cyanophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans-

(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-63-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(4-cyanophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-65-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(cyanomethyl)-1,2,3,5-tetrahydro-1-(1-methylethyl)-2-oxo-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 152910-67-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(cyanomethyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-, trans- (9CI) (CA INDEX NAME)

NAME)


Relative stereochemistry.



RN 152911-36-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(cyanomethyl)-
1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans- (9CI) (CA INDEX
NAME)

Relative stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:21418 CAPLUS Full-text

DN 128:75386

TI Preparation of benzoxazepinone derivs. as squalene synthetase inhibitors

IN Bell, Andrew Simon; Hamanaka, Ernest Seiichi; Hayward, Cheryl Myers;

Scully, Douglas Alan; Stammen, Blanda Luzia Christa

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 42 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 814080	A1	19971229	EP 1997-304225	19970617
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 5965553	A	19991012	US 1997-874089	19970612
	CA 2208174	A1	19971220	CA 1997-2208174	19970618
	JP 10059953	A	19980303	JP 1997-162353	19970619
PRAI	US 1996-19894P	P	19960620		
OS	MARPAT 128:75386				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention relates to certain benzoxazepinones and benzothiazepinones of Formula[I; X = O, S(O), or SO₂; R₁, R₂, R₂₀ = H, halo, OH, CF₃, C₁-4 alkyl, etc; R₄ = C₁-4 alkenyl, C₁-7 alkyl, C₃-4 cycloalkylmethyl, C₁-7 alkenyl, het(C₁-6)alkyl wherein het is a 4-7 member (un)saturated heterocycle containing independently 1 - 3 O, N, or S atoms; Z = CO₂H, C₁-4 alkoxycarbonyl, mono-N or di-N,N-(C₁-4)alkylaminocarbonyl, NHCO, cyano or HONHCO] useful as hypocholesterolemic agents, hypotriglyceridemic agents, antiatherosclerosis agents, antifungal agents, Alzheimer's agents or anti-acne agents. Thus, II was fermented with *Streptomyces griseus* in IOWA Medium to give 2.7 mg of III in 11% process yield.

IT 200567-79-9P 200567-80-2P 200567-86-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxazepinone derivs. as squalene synthetase inhibitors for treatment of diseases)

RN 200567-79-9 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-[3-(dimethylamino)-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-5-(1-naphthalenyl)-2-oxo-, trans- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 200567-80-2 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-[2,2-dimethyl-3-(4-morpholinyl)propyl]-1,2,3,5-tetrahydro-5-(1-naphthalenyl)-2-oxo-, trans-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 200567-86-8 CAPLUS
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1,2,3,5-tetrahydro-1-[4-(2-methyl-1H-imidazol-1-yl)butyl]-5-(1-naphthalenyl)-2-oxo-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L13 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:317788 CAPLUS Full-text

DN 126:293368

TI Benzoxazepine compounds, their production and use as lipid lowering agents

IN Yukimasa, Hidefumi; Sugiyama, Yasuo; Tozawa, Ryuichi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9710224	A1	19970320	WO 1996-JP2596	19960912
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2231052	A1	19970320	CA 1996-2231052	19960912
	CA 2231052	C	20071113		
	AU 9669442	A	19970401	AU 1996-69442	19960912
	JP 09136880	A	19970527	JP 1996-242378	19960912
	JP 3479796	B2	20031215		
	EP 862562	A1	19980909	EP 1996-930365	19960912
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1196052	A	19981014	CN 1996-196892	19960912
	CN 1072649	B	20011010		
	EP 1097928	A1	20010509	EP 2000-126672	19960912
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 202774	T	20010715	AT 1996-930365	19960912
	ES 2158344	T3	20010901	ES 1996-930365	19960912
	PT 862562	T	20011130	PT 1996-930365	19960912
	ZA 9702134	A	19990604	ZA 1997-2134	19970312
	US 6110909	A	20000829	US 1998-43265	19980312
	US 6613761	B1	20030902	US 2000-587947	20000606
	JP 2001097963	A	20010410	JP 2000-323310	20001018
	JP 4021612	B2	20071212		
	GR 3036707	T3	20011231	GR 2001-401564	20010926
	US 2004072819	A1	20040415	US 2003-606152	20030624
	US 2007117787	A1	20070524	US 2006-638066	20061212
	JP 2007332154	A	20071227	JP 2007-210503	20070810
PRAI	JP 1995-235457	A	19950913		
	EP 1996-930365	A3	19960912		
	JP 1996-242378	A3	19960912		
	WO 1996-JP2596	W	19960912		
	ZA 1997-2134	A	19970312		
	US 1998-43265	A3	19980312		
	US 2000-587947	A1	20000606		
	JP 2000-323310	A3	20001018		
	US 2003-606152	B1	20030624		


OS MARPAT 126:293368

GI




- AB New benzoxazepines I [R = alkyl, hydroxyalkyl; R1 = alkyl; R2 = halogen; R3 = (un)substituted CONH2, heterocyclic group having a deprotonatable hydrogen atom] were prepared for use as cholesterol and triglyceride lowering agent. Thus, I [R = CH2CMe3, R1 = Me, R2 = Cl, R3 = CO2H] was amidated, dehydrated to the nitrile, and cyclized with Me3SiN3 to give I [R = CH2CMe3, R1 = Me, R2 = Cl, R3 = 5-tetrazolyl] which had a squalene synthetase inhibiting IC50 of 11X10⁻⁹ M.
- IT 189059-83-4P 189059-90-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of arylbenzoxazepinones as hypolipemic agents)
- RN 189059-83-4 CAPLUS
- CN 4-Piperidinecarboxamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-(methylsulfonyl)-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RN 189059-90-3 CAPLUS
- CN 4-Piperidineacetamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-(methylsulfonyl)-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 189058-50-2P 189058-52-4P 189058-63-7F
 189058-64-8F 189059-40-3P 189059-42-5P
 189059-62-9P 189059-63-0P 189059-64-1P
 189059-94-7F 189059-95-9P 189060-41-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylbenzoxazepinones as hypolipemic agents)

RN 189058-50-2 CAPLUS

CN L-Asparagine, N2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-52-4 CAPLUS

CN L-Glutamine, N2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-63-7 CAPLUS

CN L-Histidine, N-[[[(3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-64-8 CAPLUS

CN L-Tryptophan, N-[[[(3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-40-3 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-,

(3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-42-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-62-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-(3-cyanopropyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-63-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-N-(3-cyanopropyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-64-1 CAPLUS

CN 1H-Tetrazole-1-propanenitrile, 5-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-94-7 CAPLUS

CN 4-Piperidineacetamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-95-8 CAPLUS

CN 4-Piperidineacetonitrile, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-41-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-(1-pyrrolidinyl)ethyl)-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 189058-90-0P 189058-92-2P 189059-03-8P
 189059-04-9P 189059-11-8P 189059-12-9P
 189059-13-0P 189059-14-1P 189059-16-3P
 189059-17-4P 189059-18-5P 189059-19-6P
 189059-20-9P 189059-21-0P 189059-22-1P
 189059-23-2P 189059-35-0P 189059-41-4P
 189059-49-2P 189059-50-5P 189059-76-3P
 189059-77-6P 189060-37-5P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylbenzoxazepinones as hypolipemic agents)

RN 189058-90-0 CAPLUS

CN L-Asparagine, N2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-92-2 CAPLUS

CN L-Glutamine, N2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-03-8 CAPLUS

CN L-Histidine, N-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-04-9 CAPLUS

CN L-Tryptophan, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-11-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(3-aminopropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 189059-12-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[2-(4-morpholinyl)ethyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-13-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-piperidiny)ethyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-14-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[3-(1-piperidiny)propyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-16-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-N-[[4-(dimethylamino)phenyl]methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-17-4 CAPLUS

CN 4-Piperidinamine, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N,N-dimethyl-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-18-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[3-(3,4-dihydro-2(1H)-isoquinolinyl)propyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-

1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-19-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-20-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[3-(4-morpholinyl)propyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-21-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[3-(1-pyrrolidinyl)propyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-22-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-pyridinylmethyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-23-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-39-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-[[4-(aminosulfonyl)phenyl]methyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-41-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-49-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(1H-tetrazol-5-ylmethyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-50-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-1H-tetrazol-5-yl-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-70-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-77-6 CAPLUS

CN 4-Piperidineacetamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-(methylsulfonyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-37-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:14595 CAPLUS Full-text

DN 126:59976

TI Preparation of benzothiazepinones as cholecystokinin antagonists

IN Yukimasa, Hidefumi; Miki, Takashi

PA Takeda Chemical Industries Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 16 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08259447	A	19961008	JP 1995-66180	19950324
PRAI	JP 1995-66180		19950324		
OS	MARPAT 126:59976				

GI For diagram(s), see printed CA Issue.

AB The title compds. I [ring A = (un)substituted benzene ring, etc.; R1 - R3 = H, (un)substituted hydrocarbon; X = bond, etc.; ring B = (un)substituted Ph, etc.; Z = O, etc.] are prepared In an in vitro test, the title compound II (preparation given) at 0.1 μ M gave 80% [3H]-CCK-8 binding inhibition.

IT 184881-95-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzothiazepinones as cholecystokinin antagonists)

RN 184881-95-6 CAPLUS

CN Urea, N-[7-chloro-5-(2,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]-N'-(3-methylphenyl)-, (3R-cis)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1994:164246 CAPLUS Full-text

DN 120:164246

TI 4,1-Benzoxazepines as squalene synthase inhibitors and their use in the treatment of hypercholesterolemia and as fungicides

IN Yukimasa, Hidefumi; Tozawa, Ryuichi; Kori, Masakuni; Kitano, Kazuaki

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 194 pp.


CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 567026	A1	19931027	EP 1993-106276	19930417
	EP 567026	B1	20030326		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	SG 82630	A1	20010821	SG 1999-3981	19930417
	AT 235474	T	20030415	AT 1993-106276	19930417
	AU 9337003	A	19931021	AU 1993-37003	19930419
	AU 659543	B2	19950518		
	CA 2094335	C	19931021	CA 1993-2094335	19930419
	CA 2094335	A1	19931021		
	NO 9301433	A	19931021	NO 1993-1433	19930419
	NO 304520	B1	19990104		
	RU 2145603	C1	20000220	RU 1993-5332	19930419
	CN 1083481	A	19940309	CN 1993-106358	19930420
	CN 1044237	B	19990721		
	JP 06239843	A	19940830	JP 1993-117857	19930420
	JP 3283628	B2	20020520		
	HU 71482	A2	19951128	HU 1993-1164	19930420
PRAI	JP 1992-99541	A	19920420		
	JP 1992-339947	A	19921221		
OS	MARPAT 120:164246				
GI					



I

AB The titled comps. I [R1 = H, (un)substituted hydrocarbon group; R2, R3 = H, (un)substituted lower alkyl, (un)substituted Ph or aromatic heterocyclic group; X = direct bond, Z1-7 bridging group; Y = optionally esterified or thioesterified carboxyl group, (un)substituted OH, (un)substituted NH2, (un)substituted Ph, (un)substituted carbamoyl, etc.; ring A may be optionally substituted], which demonstrate inhibition of pathogenic fungal growth and inhibition of the enzyme squalene synthetase, are prepared and I-containing formulations presented. Thus, the Et ester of N-[(3-R,5-S)-7-chloro-5-(2-chlorophenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-

acetylaminocetate was hydrolyzed in NaOH solution, producing N-[(3R,5S)-7-chloro-5-(2-chlorophenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]aminoacetic acid (II). II demonstrated 50% inhibitory concentration against human squalene synthetase of 0.06×10^{-7} M.

IT 152910-61-7P 152910-63-9P 152910-67-3P

152910-73-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of benzoxazepine fungicides


and

squalene synthase inhibitors)

RN 152910-61-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(3-cyanophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-63-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(4-cyanophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-67-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(cyanomethyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-, trans-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 152910-73-1 CAPLUS

CN 4,1-Benzoxazepine-3-propanal, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-, α -(hydroxyhydrazone), trans-(9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.



IT 152907-99-8P 152908-00-4P 152908-01-5P
 152908-02-6P 152908-03-7P 152908-04-8P
 152908-07-1P 152908-11-7P 152908-27-5P
 152908-30-0P 152908-33-3P 152908-55-9P
 152908-56-0P 152908-75-3P 152908-76-4P
 152910-21-9P 152910-22-0P 152910-23-1P
 152910-24-2P 152910-25-3P 152910-27-5P
 152910-28-6P 152910-60-6P 152910-62-8P
 152910-64-0P 152910-66-2P 152911-35-8P
 152911-36-9P 152984-64-0P 152984-65-1P
 152984-66-2P 152984-68-4P 152984-72-0P
 152984-73-1P 152984-74-2P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and squalene synthase inhibitory activity and fungicidal activity of)

RN 152907-99-8 CAPLUS

CN L-Tryptophan, N-[1-oxo-3-[1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]propyl]-, methyl ester, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-00-4 CAPLUS

CN L-Tryptophan, N-[1-oxo-3-[(1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-(phenylmethyl)-4,1-benzoxazepin-3-yl)propyl]-, (3R-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-01-5 CAPLUS

CN L-Tryptophan, N-[3-[(7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl)-1-oxopropyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-02-6 CAPLUS

CN L-Tryptophan, N-[3-[(7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl)-1-oxopropyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-03-7 CAPLUS

CN D-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-phenylmethyl]-4,1-benzoxazepin-3-yl]-1-oxopropyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-04-8 CAPLUS

CN D-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-3-yl]-1-oxopropyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 152908-07-1 CAPLUS

CN L-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-

(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-11-7 CAPLUS

CN Glycine, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-N-(1H-indol-3-ylmethyl)-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152908-27-5 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-30-0 CAPLUS

CN L-Tryptophan, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152908-33-3 CAPLUS

CN Glycine, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-N-(1H-indol-3-ylmethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152908-55-9 CAPLUS

CN Glycine, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]methyl]amino]carbonyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152908-56-0 CAPLUS

CN Glycine, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-phenylmethyl]-4,1-benzoxazepin-3-yl]methyl]amino]carbonyl]-, trans- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 152908-75-3 CAPLUS

CN L-Tryptophan, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-phenylmethyl]-4,1-benzoxazepin-3-yl]carbonyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 152908-76-4 CAPLUS

CN L-Tryptophan, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-phenylmethyl]-4,1-benzoxazepin-3-yl]carbonyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, hydrazide, trans- (9CI) (CA INDEX NAME)

CN 4,1-Benzoxazepine-3-acetic acid, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, 2,2-dimethylhydrazide, trans-(9CI) (CA INDEX NAME)

RN 152910-23-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-N-(1H-tetrazol-5-yl)-, trans- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 152910-24-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(3-amino-3-oxopropyl)-7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(1-methylethyl)-2-oxo-, trans- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 152910-25-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-[[4-(dimethylamino)phenyl]methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-27-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-[3-(dimethylamino)propyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-28-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-60-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[3-(1H-tetrazol-5-yl)phenyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-62-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(4-(1H-tetrazol-5-yl)phenyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-64-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(1-methylethyl)-2-oxo-N-(1H-tetrazol-5-ylmethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152910-66-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-N-(1H-tetrazol-5-ylmethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152911-35-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(1H-tetrazol-5-ylmethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152911-36-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(cyanomethyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152984-64-0 CAPLUS

CN L-Tryptophan, N-[1-oxo-3-[1,2,3,5-tetrahydro-2-oxo-5-phenyl-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]propyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152984-65-1 CAPLUS

CN D-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]-1-oxopropyl]-, (3R-trans)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 152984-66-2 CAPLUS

CN L-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 152984-68-4 CAPLUS


CN D-Tryptophan, N-[3-[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)-, butanoate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152984-67-3

CMF C36 H31 Cl2 N3 O5


Absolute stereochemistry.



CM 2

CRN 107-92-6


CMF C4 H8 O2



RN 152984-72-0 CAPLUS

CN L-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152984-73-1 CAPLUS

CN D-Tryptophan, N-[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-(phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152984-74-2 CAPLUS

CN D-Tryptophan, N-[[[7-chloro-5-(2-chlorophenyl)-1,2,3,5-tetrahydro-2-oxo-1-phenylmethyl)-4,1-benzoxazepin-3-yl]acetyl]-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 152910-65-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of benzoxazepine fungicides and squalene synthase inhibitors)

RN 152910-65-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2-chlorophenyl)-N-(cyanomethyl)-1,2,3,5-tetrahydro-1-(1-methylethyl)-2-oxo-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




=> d l2; d l7; d l10; d his; log y
L2 HAS NO ANSWERS
L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

L7 HAS NO ANSWERS
L6 STR



Structure attributes must be viewed using STN Express query preparation.
L7 QUE ABB=ON PLU=ON L6

L10 HAS NO ANSWERS
L9 STR



Structure attributes must be viewed using STN Express query preparation.
L10 QUE ABB=ON PLU=ON L9

(FILE 'REGISTRY' ENTERED AT 23:12:29 ON 17 JAN 2008)

DEL HIS Y
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 2 S L2
L4 14 S L2 FUL

FILE 'CAPLUS' ENTERED AT 23:13:17 ON 17 JAN 2008

L5 1 S L4

FILE 'REGISTRY' ENTERED AT 23:14:48 ON 17 JAN 2008

L6 STRUCTURE UPLOADED
L7 QUE L6
L8 50 S L7
L9 STRUCTURE UPLOADED
L10 QUE L9
L11 45 S L10
L12 871 S L10 FUL

FILE 'CAPLUS' ENTERED AT 23:16:45 ON 17 JAN 2008
L13 15 S L12

FILE 'STNGUIDE' ENTERED AT 23:18:53 ON 17 JAN 2008

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.18	449.11
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-12.80

STN INTERNATIONAL LOGOFF AT 23:20:47 ON 17 JAN 2008